On the role of subtype selective adenosine receptor agonists during proliferation and osteogenic differentiation of human primary bone marrow stromal cells

Journal of Cellular Physiology

Volumn 226, Issue 5, 2011, Pages 1353-1366

  Costa, M Adelina ^a   Barbosa, A ^a   Neto, E ^a   Sa E Sousa A ^a   Freitas, R ^b   Neves, J M ^b   Magalhaes Cardoso T ^a   Ferreirinha, F ^a   Correia De Sa P ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b Centro Hospitalar de VN Gaia   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 FURANYL) 7 [3 (4 METHOXYPHENYL)PROPYL] 7H PYRAZOLO [4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDIN 5 AMINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 [4 (2 P CARBOXYETHYL)PHENYLAMINO] 5' N ETHYLCARBOXAMIDO ADENOSINE; 2 CHLORO N6 (3 IODOBENZYL) ADENOSINE 5' METHYLURONAMIDE; 3 ETHYL 5 BENZYL 2 METHYL 4 PHENYLETHYNYL 6 PHENY 1,4 DIHYDROPYRIDINE 3,5 DICARBOXYLATE; 6 N CYCLOPENTYLADENOSINE; 8 [4 [4 (4 CHLOROPHENZYL)PIPERAZIDE 1 SULFONYL)PHENYL]] 1 PROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR STIMULATING AGENT; ADENOSINE TRIPHOSPHATE; ALKALINE PHOSPHATASE; DIPYRIDAMOLE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL;

ADENOSINE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OSTEOBLASTS; OSTEOGENESIS; PURINERGIC P1 RECEPTOR AGONISTS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1; STROMAL CELLS; TIME FACTORS;

EID: 79951807194     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22458     Document Type: Article

References (52)

1. Arch JRS, Newsholme EA. 1978. The control of metabolism and the hormonal role of adenosine. In Essays in Biochemistry, Campbell PN, Aldridge WN, (eds). Academic Press: New York, 82-123.
2. Buckley KA, Golding SL, Rice JM, Dillon JP, Gallagher JA. 2003. Release and interconversion of P2 receptor agonists by human osteoblast-like cells. FASEB J 17: 1401-1410.
3. Cass CE, Young JD, Baldwin SA. 1998. Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochem Cell Biol 76: 761-770.
4. Chan ES, Cronstein BN. 2002. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 4: 266-273.
5. 2A receptor heteromers. J Neurosci 26: 2080-2087.
6. Coelho MJ, Cabral AT, Fernandes MH. 2000. Human bone cell cultures in biocompatibility testing. Part I: osteoblastic differentiation of serially passaged human bone marrow cells cultured in α-MEM and in DMEM. Biomaterials 21: 1087-1094.
7. Correia-de-Sá P, Adães S, Timóteo MA, Vieira C, Magalhães-Cardoso T, Nascimento C, Duarte-Araújo M. 2006. Fine-tuning modulation of myenteric motoneurons by endogenous adenosine: on the role of secreted adenosine deaminase. Auton Neurosci 126-127: 211-224.
8. 3H]acetylcholine release from the rat motor nerve terminals. Neuroscience 73: 85-92.
9. Correia-de-Sá P, Sebastião AM, Ribeiro JA. 1991. Inhibitory and excitatory effects of adenosine receptor agonists on evoked transmitter release from phrenic nerve endings of the rat. Br J Pharmacol 103: 1614-1620.
10. 2A facilitatory adenosine receptor activation balance depends on motor nerve stimulation paradigm at the rat hemidiaphragm. J Neurophysiol 76: 3910-3919.
11. Cunha RA, Correia-de-Sá P, Sebastião AM, Ribeiro JA. 1996. Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides. Br J Pharmacol 119: 253-260.
12. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, Deans RJ, Keating A, Prockop DJ, Horwitz EM. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
13. 1 receptors. Br J Pharmacol 141: 925-934.
14. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. 1997. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89: 747-754.
15. 2A receptor agonists activated by ecto-5'-Nucleotidase. J Med Chem 52: 7669-7677.
16. Eliasson L, Ma X, Renström E, Barg S, Berggren PO, Galvanovskis J, Gromada J, Jing X, Lundquist I, Salehi A, Sewing S, Rorsman P. 2003. SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic β-cells. J Gen Physiol 121: 181-197.
17. Evans BA, Elford C, Pexa A, Francis K, Hughes AC, Deussen A, Ham J. 2006. Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. J Bone Miner Res 21: 228-236.
18. Faria M, Silva-Ramos M, Magalhães-Cardoso MT, Lafuente-de-Carvalho J-M, Correia-de-Sá P. 2005. Extracellular metabolism and contractile potency of adenine nucleotides in human detrusor smooth muscle taken from patients with obstructed urinary bladder. J Neurochem 94: 127.
19. Fernandes MH, Costa MA, Carvalho GS. 1997. Mineralization in serially passaged human alveolar bone cells. J Mat Sci: Mat Med 8: 661-665.
20. Hallstrom H, Wolk A, Glynn A, Michaelsson K. 2006. Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women. Osteoporosis Int 17: 1055-1064.
21. Hoebertz A, Arnett TR, Burnstock G. 2003. Regulation of bone resorption and formation by purines and pyrimidines. Trends Pharmacol Sci 24: 290-297.
22. 2 receptors in rat brain. J Pharmacol Exp Ther 251: 888-893.
23. Johnson KA, Hessle L, Vaingankar S, Wennberg C, Mauro S, Narisawa S, Goding JW, Sano K, Millan JL, Terkeltaub R. 2000. Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol (Regul Integr Comp Physiol) 279: R1365-R1377.
24. 1 receptor-knockout mice. Arthritis Rheum 62: 534-541.
25. Kaneko M, Takahashi T. 2004. Presynaptic mechanism underlying cAMP-dependent synaptic potentiation. J Neurosci 24: 5202-5208.
26. Lei HY, Chang CP. 2009. Lectin of concanavalin A as an anti-hepatoma therapeutic agent. J Biomed Sci 16: 10.
27. Lerner UH, Sahlberg K, Fredholm BB. 1987. Characterization of adenosine receptors in bone. Studies on the effect of adenosine analogues on cyclic AMP formation and bone resorption in cultured mouse calvaria. Acta Physiol Scand 131: 287-296.
28. Liu H, Toh WS, Lu K, MacAry PA, Kemeny DM, Cao T. 2009. A subpopulation of mesenchymal stromal cells with high osteogenic potential. J Cell Mol Med 13: 2436-2447.
29. Lloyd HG, Fredholm BB. 1995. Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in rat hippocampal slices. Neurochem Int 26: 387-395.
30. 2A receptor facilitation of acetylcholine release at rat motor nerve endings. J Physiol (London) 549: 399-408.
31. Meininger CJ, Granger HJ. 1990. Mechanisms leading to adenosine-stimulated proliferation of microvascular endothelial cells. Am J Physiol (Heart Circ Physiol) 258: H198-H206.
32. Naito Y, Lowenstein JM. 1985. 5'-Nucleotidase from rat heart membranes. Inhibition by adenine nucleotides and related compounds. Biochem J 226: 645-651.
33. Orriss IR, Burnstock G, Arnett TR. 2010. Purinergic signaling and bone remodelling. Curr Op Pharmacol 10: 322-330.
34. 2 receptors and pyrophosphate. Endocrinology 148: 4208-4216.
35. Rapuri PB, Gallagher JC, Kinyamu HK, Ryschon KL. 2001. Caffeine intake increases the rate of one loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr 74: 694-700.
36. Raucci A, Bellosta P, Grassi R, Basilico C, Mansukani A. 2008. Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signalling pathways. J Cell Physiol 215: 442-451.
37. Riordan JR, Slavik M. 1974. Interactions of lectins with membrane glycoproteins effects of concanavalin A on 5'-nucleotidase. Biochim Biophys Acta 373: 356-360.
38. Russell JM, Stephenson GS, Yellowley CE, Benton HP. 2007. Adenosine inhibition of lipopolysaccharide-induced interleukin-6 secretion by the osteoblastic cell line MG-63. Calcif Tissue Int 81: 316-326.
39. Sauer AV, Mrak E, Hernandez RJ, Zacchi E, Cavani F, Casiraghi M, Grunebaum E, Roifman CM, Cervi MC, Ambrosi A, Carlucci F, Roncarolo MG, Villa A, Rubinacci A, Aiuti A. 2009. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood 114: 3216-3226.
40. Schulte G, Fredholm BB. 2003. The G(s)-coupled adenosine A(2B) receptor recruits divergent pathways to regulate ERK1/2 and p38. Exp Cell Res 290: 168-176.
41. Sebastião AM, Ribeiro JA. 2000. Fine-tuning neuromodulation by adenosine. Trends Pharmacol Sci 21: 341-346.
42. Shimegi S. 1996. ATP and adenosine act as a mitogen for osteoblast-like cells (MC3T3-E1). Calcif Tissue Int 58: 109-113.
43. Shimegi S. 1998. Mitogenic action of adenosine on osteoblast-like cells, MC3T3-E1. Calcif Tissue Int 62: 418-425.
44. Stefan C, Jansen S, Bollen M. 2005. NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci 30: 542-550.
45. Stefanovic V, Mandel P, Rosenberg A. 1975. Concanavalin A inhibition of ecto-5'-nucleotidase of intact cultured C6 glioma cells. J Biol Chem 250: 7081-7083.
46. Stehle JH, Rivkees SA, Lee JJ, Weaver DR, Deeds JD, Reppert SM. 1992. Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. Mol Endocrinol 6: 384-393.
47. Stein G, Lian J. 1995. Molecular mechanisms mediated proliferation-differentiation interrelationships during progressive development of the osteoblast phenotype: update. Eur Rev 4: 290-297.
48. Tintut Y, Parhami F, Le V Karsenty G, Demer LL. 1999. Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation. J Biol Chem 274: 28875-28879.
49. Tuli R, Tuli S, Nandi S, Wang ML, Alexander PG, Haleem-Smith H, Hozack WJ, Manner PA, Danielson KG, Tuan RS. 2003. Characterization of multipotential mesenchymal progenitor cells derived from human trabecular bone. Stem Cell 21: 681-693.
50. Uehara R, Suzuki Y, Ichikawa Y. 2001. Methotrexate (MTX) inhibits osteoblastic differentiation in vitro: possible mechanism of MTX osteopathy. J Rheumatol 28: 251-256.
51. ras by G protein-coupled receptor agonists in fibroblasts. Proc Natl Acad Sci USA 25: 22235-22238.
52. Zimmermann H. 2000. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedeberg's Arch Pharmacol 362: 299-309.